Skip to content
★ Sign in to follow
EK
Total declarations
13
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (1 ops.)
€114k

Latest filing published 10 Mar 2021 for KYNTRA BIO, INC., €146k.

Filing timeline

BuySale
Elias Kouchakji

Insider track record

Disclosed buys
0
Disclosed sells
1
Signal history

Elias Kouchakji: trading record in brief

Elias Kouchakji is a declared insider of Kyntra Bio, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 6 June 2019 to 8 March 2021, the count stands at 13 filings.

On the market, this insider has only sold: 1 sale, €114k in total. The rest of the record consists of 10 share grants and 2 option exercises.

Most recently, on 10 March 2021, the filings show a share grant worth €146k in Kyntra Bio, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Elias Kouchakji

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations13 total
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    174,225 USD12SEC
    5,221 shares@ US$33.3710.1% of flowCommon StockSEC:0001209191-21-019555:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    0SEC
    20,800 shares0Common StockSEC:0001209191-21-015010:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    114,549 USD14SEC
    2,728 shares@ US$41.9926.2% of flowCommon StockSEC:0001209191-20-062619:0
  • ◇
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    103,220 USD12SEC
    7,082 shares@ US$14.57514.7% of flowCommon StockSEC:0001209191-20-059427:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    115,012 USD13SEC
    2,728 shares@ US$42.1616.5% of flowCommon StockSEC:0001209191-20-050049:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    91,688 USD12SEC
    2,728 shares@ US$33.6111.7% of flowCommon StockSEC:0001209191-20-035694:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    259,108 USD14SEC
    6,525 shares@ US$39.7128.5% of flowCommon StockSEC:0001209191-20-020121:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    0SEC
    37,500 shares0Common StockSEC:0001209191-20-020121:1
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    115,726 USD12SEC
    2,442 shares@ US$47.398.0% of flowCommon StockSEC:0001209191-19-059778:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    230,949 USD13SEC
    5,541 shares@ US$41.6816.1% of flowCommon StockSEC:0001209191-19-049100:0
  • ▼
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    129,285 USD30SEC
    2,873 shares@ US$45.008.8% of flowCommon StockSEC:0001209191-19-040581:0
  • ◇
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    233,280 USD13SEC
    16,000 shares@ US$14.5816.1% of flowCommon StockSEC:0001209191-19-038295:0
  • ◆
    SVP, Clinical Dev, Drug SafetyExecutivesKyntra Bio, Inc.
    78,842 USD12SEC
    2,058 shares@ US$38.315.4% of flowCommon StockSEC:0001209191-19-035678:0

13 of 13 declarations